| HOME >> BIOLOGY >> TECHNOLOGY |
Irvine, CA (PRWEB) November 15, 2013
Proove Biosciences, the leading personalized pain medicine laboratory, is excited to be presenting clinical data on how its proprietary genetic testing services have been improving pain management at the American Society of Regional Anesthesia and Pain Medicine’s 12th Annual Fall Meeting. This five-day event will take place from November 20-24, at The Arizona Biltmore Hotel, in Phoenix Arizona.
The ASRA’s Meeting Panel is a gathering of internationally recognized experts in Pain Medicine who will present an exciting and relevant array of topics. Offered sessions will include refresher courses, general sessions, workshops, problem-based learning discussions, a nursing program, poster presentations and a comprehensive technical exhibition.
Proove Biosciences will be exhibiting research from two of its clinical studies and will be presenting on how their genetic testing services have been helping physicians and patients better understand how they metabolize prescription pain medication.
“The ASRA’s annual meetings address clinical and educational needs of physicians and scientists, so we are excited for the opportunity to share our findings and data with attendees,” stated Proove Biosciences President and Founder, Brian Meshkin. “We are the only company providing proprietary testing services in personalized pain medicine, and the only company that has been presenting clinical research data on the genetics of pain medicine at major scientific meetings this year. The ASRA’s meeting will allow physicians unfamiliar in these new capabilities to begin incorporating this leading-edge technology into their practice to help improve patients’ treatment on an individual level.”
About Proove Biosciences
Proove Biosciences is the leading Personalized Pain Medicine laboratory that provides proprietary genetic testing services to help physicians improve outcomes for patients and contain costs for insurers. With offices in Southern California and the Baltimore-Washington metropolitan area, the Company is the research leader investigating and publishing data on the genetics of pain medicine with clinical research sites across the United States. Physicians use Proove Biosciences testing to improve pain medicine selection, dosing, and evaluation of medications they prescribe. From a simple cheek swab collected in the office, Proove performs proprietary genetic tests in its CLIA-certified laboratory to identify patients at risk for misuse of prescription pain medications and evaluate their metabolism of medications. For more information, please visit http://www.proovebio.com or call toll free 855-PROOVE-BIO (855-776-6832).
Read the full story at http://www.prweb.com/releases/2013/11/prweb11337507.htm.
'/>"/>
| Source: PRWeb Copyright©2012 Vocus, Inc. All rights reserved |
Related biology technology :
1. Proove Biosciences Will Be Exhibiting At The 2013 Common Sense Pain Management Conference
2. Proove Biosciences Announces Sponsorship of National Drug Take Back Day and HC DrugFree
3. Proove Biosciences Continues Its Research Leadership in the Genetics of Pain Medicine at The American Academy of Pain Management’s 24th Annual Meeting
4. Proove CEO and Vice Chairman of the Howard County Board of Education, Brian Meshkin, Selected as one of Howard County's Finest Under 39 by the Cystic Fibrosis Foundation
5. Proove Biosciences Will Participate at the California Society of Interventional Pain Physician’s 4th Annual Meeting This Weekend
6. Sangamo BioSciences Announces Presentation Of Clinical Data From Alzheimers Disease Program
7. Ambit Biosciences Announces Third Quarter 2013 Operating Results
8. Pressure BioSciences, Inc. Reports Third Quarter 2013 Financial Results and Provides Business Update
9. Juneau Biosciences Names Dr. Dinesh Patel to Board of Directors
10. Pressure BioSciences, Inc. to Discuss Third Quarter 2013 Financial Results and Provide a Business Update
11. Regado Biosciences, Inc. Appoints World-Renowned Leader in Cardiovascular Research and Former Global Head of Cardiovascular Diseases for Merck & Co., to Board of Directors
| Copyright © 2003-2012 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |